anti-EGFR ADC

Anti-EGFR ADCs are a class of antibody-drug conjugates designed to target the epidermal growth factor receptor (EGFR), a protein often overexpressed in various solid tumors such as lung, colorectal, and head and neck cancers. These agents consist of an anti-EGFR monoclonal antibody conjugated to a potent cytotoxic payload via a chemical linker. The antibody component provides specificity, binding to EGFR on the surface of cancer cells and facilitating the internalization of the ADC. Once inside the cell, the linker is typically cleaved, releasing the payload (e.g., microtubule inhibitors or topoisomerase inhibitors) to induce cell death. While several anti-EGFR ADCs have entered clinical development, they often face challenges related to on-target, off-tumor toxicity in tissues like the skin and eyes where EGFR is normally expressed.

Other names

EGFR ADCEGFR-targeting ADCanti-EGFR antibody-drug conjugate